drugset
drugset / Trial / NCT03817346

Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers

NCT03817346 ↗

Phase 1 Completed 32 enrolled Gabather AB Smerud Medical Research International AS · collab
RandomizedParallel-groupTriple-blindBasic science

Summary

This study does not target any disease or condition in itself, but is evaluating the safety, tolerability and pharmacokinetics of single oral doses of GT-002 in the setting of healthy volunteers. A longer-term objective is to apply the findings from this study to design and later conduct a clinical development programme of GT-002 as a medication to treat schizophrenia.

Timeline

Start
2018-12-17
Primary completion
2019-03-31
Completion
2019-05-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator GT-002 Unknown — Oral

Indications

No indication recorded.